戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 se fluticasone propionate were found to have adrenal suppression.
2 is devoid of the chemical moieties producing adrenal suppression.
3 c dexamethasone (p </= .05), consistent with adrenal suppression.
4 linically significant hypothalamic-pituitary-adrenal suppression and cutaneous atrophy in children.
5 st specifically related to the potential for adrenal suppression and growth retardation.
6 unctioning in patients with the disorder but adrenal suppression and symptom recurrence on treatment
7 y be administered therapeutically to prevent adrenal suppression and worse outcomes.
8  other additional treatments when faced with adrenal suppression as a side effect of steroids or loss
9  pruritus, and they had striae and secondary adrenal suppression as side effects of steroids.
10   Seven studies addressed the development of adrenal suppression associated with the administration o
11 acological doses of corticoids may result in adrenal suppression but with individual sensitivity.
12  age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391, age: 5-18, UK) to t
13  initiation of vasopressor use and decreases adrenal suppression compared with etomidate.
14 al records data including the development of adrenal suppression in 2 independent asthma cohorts.
15                                              Adrenal suppression in patients with asthma treated with
16 about adverse effects, especially growth and adrenal suppression, induced by systemic CS in children.
17                                              Adrenal suppression may occur in at least one fifth of t
18 pionate are used, growth may be retarded and adrenal suppression may occur.
19 mprovement in symptoms of CFS, the degree of adrenal suppression precludes its practical use for CFS.
20 ents may be at increased risk for developing adrenal suppression related to ICS use may help provider
21 .00; moderate certainty) and results in less adrenal suppression (RR, 0.54; 95% CI, 0.45-0.66; modera
22 es < 20 nmol/l are undetectable and indicate adrenal suppression, values > 69 nmol/l are considered t
23 ticoids should be subjected to screening for adrenal suppression when anticipated discontinuation of
24 alance between minimizing adverse effects of adrenal suppression while capitalizing on the establishe
25    The discovery cohort (Pharmacogenomics of Adrenal Suppression with Inhaled Corticosteroids) includ
26 vironment Study, and the Pharmacogenetics of Adrenal Suppression with Inhaled Steroid Study).